Zomedica Corp. (NYSEAMERICAN:ZOM – Get Free Report) CEO Larry C. Heaton II acquired 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was purchased at an average price of $0.12 per share, with a total value of $12,000.00. Following the completion of the acquisition, the chief executive officer now owns 400,000 shares in the company, valued at $48,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Zomedica Stock Down 0.4 %
Shares of NYSEAMERICAN ZOM opened at $0.13 on Friday. Zomedica Corp. has a twelve month low of $0.12 and a twelve month high of $0.23. The company has a market capitalization of $124.65 million, a P/E ratio of -3.20 and a beta of 1.03.
Hedge Funds Weigh In On Zomedica
Hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC grew its position in Zomedica by 1,585.0% in the 1st quarter. Virtu Financial LLC now owns 168,773 shares of the company’s stock worth $25,000 after purchasing an additional 158,757 shares during the period. Frazier Financial Advisors LLC bought a new stake in Zomedica in the 4th quarter worth approximately $50,000. Finally, Price T Rowe Associates Inc. MD grew its position in Zomedica by 41.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 948,300 shares of the company’s stock worth $139,000 after purchasing an additional 276,100 shares during the period. 8.95% of the stock is currently owned by hedge funds and other institutional investors.
About Zomedica
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Further Reading
- Five stocks we like better than Zomedica
- What is the Nikkei 225 index?
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- ESG Stocks, What Investors Should Know
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- Dividend Capture Strategy: What You Need to Know
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.
